Targeting of CXCR3 improves anti-myeloma efficacy of adoptively transferred activated natural killer cells

ConclusionsOur results demonstrate that in vitro activation affects NK cell anti-myeloma activity in vivo by regulating their BM infiltration. Furthermore, we provided direct evidence that CXCR3 restrains NK cell anti-tumor capacity in vivo according to the activation protocol used, and that the effects of NK cell-based adoptive immunotherapy for multiple myeloma can be improved by increasing their bone marrow homing through CXCR3 inhibition.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research